Overview

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Status:
Withdrawn
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effects of MK0822 in prolonging the time to first bone metastasis in men with castration-resistant prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.